Stockwatch: 2015 - Year of the Grinch?
This article was originally published in Scrip
2014 drew to a close in a stock market bloodbath. It mirrored the havoc caused earlier in the year when US politicians – prompted by pharmacy benefit managers (PBMs) – questioned the prices for newly launched and life-saving drugs (scripintelligence.com, 25 March 2014).
You may also be interested in...
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.